These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 27121944)

  • 21. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
    Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
    Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.
    Watabe M; Cheng YF; Nilsson D; Itoh Y; Kumagai Y
    Curr Med Res Opin; 2007 Aug; 23(8):1849-57. PubMed ID: 17605894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
    Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
    Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
    Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells.
    Yamasaki M; Oda K; Ichinose T; Mizuguchi M; Tominaga S; Omoda K; Mori N; Maeda Y; Nishida T; Murakami T
    Oncol Lett; 2022 Nov; 24(5):386. PubMed ID: 36238357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
    Shah AK; Hunt TL; Gallagher SC; Cullen MT
    Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.
    Clark AM; Kriel RL; Leppik IE; White JR; Henry TR; Brundage RC; Cloyd JC
    Epilepsia; 2013 Jun; 54(6):1106-11. PubMed ID: 23586686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
    Gore L; Chawla S; Petrilli A; Hemenway M; Schissel D; Chua V; Carides AD; Taylor A; Devandry S; Valentine J; Evans JK; Oxenius B;
    Pediatr Blood Cancer; 2009 Feb; 52(2):242-7. PubMed ID: 18985740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
    Yamasaki M; Kimura R; Mayahara S; Maeda Y; Takahashi M; Nishida T; Oda K; Murakami T
    Mol Clin Oncol; 2019 Jul; 11(1):43-49. PubMed ID: 31289676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist Vestipitant.
    Brigandi RA; Russ SF; Petit C; Johnson B; Croy S; Hodsman P; Muller F
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):130-136. PubMed ID: 26097793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions.
    Gonçalves SC; Sanches SM; Bueno CT; Villela de Castro DL; Damascena A; Santos GRC
    J Infus Nurs; 2017; 40(6):380-383. PubMed ID: 29112587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infusion reactions following administration of intravenous rolapitant at an academic medical center.
    Cass AS; Odinet JS; Valgus JM; Crona DJ
    J Oncol Pharm Pract; 2019 Oct; 25(7):1776-1783. PubMed ID: 30348072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.